The	the	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
short-term	short-term	O	O	O	O
raloxifene	raloxifene	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
on	on	O	O	O	O
fibrinolysis	fibrinolysis	O	O	O	O
markers	markers	O	O	O	O
:	:	O	O	O	O
TAFI	tafi	O	O	O	O
,	,	O	O	O	O
tPA	tpa	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
PAI-1.BACKGROUND	pai-1.background	O	O	O	O
:	:	O	O	O	O
Markers	markers	O	O	O	O
of	of	O	O	O	O
fibrinolysis	fibrinolysis	O	O	O	O
,	,	O	O	O	O
thrombin-activatable	thrombin-activatable	O	O	O	O
fibrinolysis	fibrinolysis	O	O	O	O
inhibitor	inhibitor	O	O	O	O
(	(	O	O	O	O
TAFI	tafi	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
tissue-type	tissue-type	O	O	O	O
plasminogen	plasminogen	O	O	O	O
activator	activator	O	O	O	O
(	(	O	O	O	O
tPA	tpa	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
plasminogen	plasminogen	O	O	O	O
activator	activator	O	O	O	O
inhibitor-1	inhibitor-1	O	O	O	O
(	(	O	O	O	O
PAI-1	pai-1	O	O	O	O
)	)	O	O	O	O
levels	levels	O	O	O	O
were	were	O	O	O	O
studied	studied	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
evaluation	evaluation	O	O	O	O
of	of	O	O	O	O
short-term	short-term	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
raloxifene	raloxifene	CHEMICALS	O	OTHERS	I
administration	administration	O	O	O	O
in	in	O	O	O	O
postmenopausal	postmenopausal	O	O	O	O
women	women	O	O	O	O
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
Thirty-nine	thirty-nine	O	O	O	O
postmenopausal	postmenopausal	O	O	O	O
women	women	O	O	O	O
with	with	O	O	O	O
osteopenia	osteopenia	O	O	OTHERS	I
or	or	O	O	O	O
osteoporosis	osteoporosis	O	DISEASE	OTHERS	I
were	were	O	O	O	O
included	included	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
prospective	prospective	O	O	O	O
,	,	O	O	O	O
controlled	controlled	O	O	O	O
clinical	clinical	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

Twenty-five	twenty-five	O	O	O	O
women	women	O	O	O	O
were	were	O	O	O	O
given	given	O	O	O	O
raloxifene	raloxifene	CHEMICALS	O	OTHERS	I
hydrochloride	hydrochloride	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
60	60	O	O	O	O
mg/day	mg/day	O	O	O	O
)	)	O	O	O	O
plus	plus	O	O	O	O
calcium	calcium	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
500	500	O	O	O	O
mg/day	mg/day	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Age-matched	age-matched	O	O	O	O
controls	controls	O	O	O	O
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
14	14	O	O	O	O
)	)	O	O	O	O
were	were	O	O	O	O
given	given	O	O	O	O
only	only	O	O	O	O
calcium	calcium	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Plasma	plasma	O	O	O	O
TAFI	tafi	O	O	O	O
,	,	O	O	O	O
tPA	tpa	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
PAI-1	pai-1	O	O	O	O
antigen	antigen	O	O	O	O
levels	levels	O	O	O	O
were	were	O	O	O	O
measured	measured	O	O	O	O
at	at	O	O	O	O
baseline	baseline	O	O	O	O
and	and	O	O	O	O
after	after	O	O	O	O
3	3	O	O	O	O
months	months	O	O	O	O
of	of	O	O	O	O
treatment	treatment	O	O	O	O
by	by	O	O	O	O
commercially	commercially	O	O	O	O
available	available	O	O	O	O
ELISA	elisa	O	O	O	O
kits	kits	O	O	O	O
.	.	O	O	O	O

Variations	variations	O	O	O	O
of	of	O	O	O	O
individuals	individuals	O	O	O	O
were	were	O	O	O	O
assessed	assessed	O	O	O	O
by	by	O	O	O	O
Wilcoxon	wilcoxon	O	O	O	O
's	's	O	O	O	O
test	test	O	O	O	O
.	.	O	O	O	O

Relationship	relationship	O	O	O	O
between	between	O	O	O	O
those	those	O	O	O	O
markers	markers	O	O	O	O
and	and	O	O	O	O
demographic	demographic	O	O	O	O
characteristics	characteristics	O	O	O	O
were	were	O	O	O	O
investigated	investigated	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Three	three	O	O	O	O
months	months	O	O	O	O
of	of	O	O	O	O
raloxifene	raloxifene	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
was	was	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
significant	significant	O	O	O	O
decrease	decrease	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
plasma	plasma	O	O	O	O
TAFI	tafi	O	O	O	O
antigen	antigen	O	O	O	O
concentrations	concentrations	O	O	O	O
(	(	O	O	O	O
16	16	O	O	O	O
%	%	O	O	O	O
change	change	O	O	O	O
,	,	O	O	O	O
P	p	O	O	OTHERS	I
<	<	O	O	O	O
0.01	0.01	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
a	a	O	O	O	O
significant	significant	O	O	O	O
increase	increase	O	O	O	O
in	in	O	O	O	O
tPA	tpa	O	O	O	O
antigen	antigen	O	O	O	O
concentrations	concentrations	O	O	O	O
(	(	O	O	O	O
25	25	O	O	O	O
%	%	O	O	O	O
change	change	O	O	O	O
,	,	O	O	O	O
P	p	O	O	OTHERS	I
<	<	O	O	O	O
0.05	0.05	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
significant	significant	O	O	O	O
correlation	correlation	O	O	O	O
was	was	O	O	O	O
found	found	O	O	O	O
between	between	O	O	O	O
baseline	baseline	O	O	O	O
TAFI	tafi	O	O	O	O
antigen	antigen	O	O	O	O
concentrations	concentrations	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
duration	duration	O	O	O	O
of	of	O	O	O	O
amenorrhea	amenorrhea	O	O	OTHERS	I
(	(	O	O	O	O
P	p	O	O	OTHERS	I
<	<	O	O	O	O
0.05	0.05	O	O	O	O
;	;	O	O	O	O
r	r	O	O	O	O
=	=	O	O	O	O
0.33	0.33	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
We	we	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
the	the	O	O	O	O
increased	increased	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
venous	venous	O	DISEASE	OTHERS	I
thromboembolism	thromboembolism	O	DISEASE	OTHERS	I
due	due	O	O	O	O
to	to	O	O	O	O
raloxifene	raloxifene	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
related	related	O	O	O	O
to	to	O	O	O	O
increased	increased	O	O	O	O
tPA	tpa	O	O	O	O
levels	levels	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
not	not	O	O	O	O
TAFI	tafi	O	O	O	O
levels	levels	O	O	O	O
.	.	O	O	O	O

